TARS

Tarsus Pharmaceuticals, Inc.

• TipRanks·1d ago

  Tarsus Pharmaceuticals Completes Alkeus Retinal Therapy Acquisition

• Dow Jones·3d ago

  Tarsus Pharmaceuticals Is Maintained at Buy by Jefferies

• Benzinga·3d ago

  Jefferies Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $105

• TipRanks·3d ago

  Tarsus Pharmaceuticals price target raised to $105 from $88 at Jefferies

• TipRanks·3d ago

  Dennis Ding Reiterates Buy on Tarsus, Highlighting Robust Xdemvy Trends, Conservative 2026 Guidance, and Attractive Valuation Backed by Late-Stage Pipeline

• NASDAQ·09/04 13:16

  Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

• Dow Jones·09/04 12:38

  *Tarsus Pharmaceuticals Completes Acquisition Of Alkeus Pharmaceuticals, Expanding Leadership In Eye Care >TARS

• Seeking Alpha·08/26 14:42

  Tarsus acquisition of Alkeus granted FTC early termination

• Benzinga·08/24 12:31

  Alkeus Pharmaceuticals Receives Orphan Drug Designation From Japan's Ministry Of Health, Labour, And Welfare For Oral Gildeuretinol To Treat Stargardt Disease

• Simply Wall St·08/18 05:21

  Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention?

• Simply Wall St·08/16 14:21

  Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next

• Dow Jones·08/12 15:26

  Tarsus Pharmaceuticals Price Target Raised to $100.00/Share From $97.00 by Oppenheimer

• Dow Jones·08/12 15:26

  Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer

• Benzinga·08/12 15:16

  Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100

• TipRanks·08/12 15:05

  Tarsus Pharmaceuticals: Buy Rating Backed by Xdemvy Outperformance and Alkeus Acquisition-Driven Pipeline Expansion